METHOCEL™ Premium CR Cellulose Ethers
First choice for the formulation of hydrophilic matrix systems, providing a robust mechanism for the extended/controlled release of drugs from oral solid dosage forms. With a choice of viscosity grades METHOCEL™ premium cellulose ethers provide a simple solution to meet a range of drug solubility needs. Tablets are easily manufactured with existing, conventional equipment and processing methods.
Matrix Tablet Formulations
| Application | Benefits | Typically Used METHOCEL Cellulose Ethers |
|---|---|---|
| Low Solubility Drugs | Fast polymer hydration to form gel layer; non-ionic | E50LV, K100LV, K100LV CR |
| Med to High Solubility Drug | Fast polymer hydration to form gel layer; non-ionic |
K4M, K15M, K100M, E4M, E10M, K4MCR, K15MCR, K100MCR, E4MCR, E10MCR |
Now available as directly compressible grades, METHOCEL™ DC2 polymers deliver exceptional flow properties and process capability as well as consistent modified release performance for matrix formulations. METHOCEL DC2 will enable manufacturers to replace costly wet granulation in matrix tablet production with cost effective dry granulation and direct compression techniques.
Three direct compression grades of METHOCEL DC2 are now available: K100 LV, K4M and K100M; chemically identical to current METHOCEL Premium products and meet USP, PhEur and JPE specifications.
Colorcon has exclusive, global sales and distribution rights for METHOCEL products from Dow Pharma & Food Solutions for use in controlled release applications.
Colorcon, through the Controlled Release Alliance, has exclusive, global sales and distribution rights for METHOCEL products from Dow Pharma & Food Solutions for use in controlled release applications.
